
Cancer in Manitoba

2020 ANNUAL STATISTICAL REPORT



CancerCareManitoba
ActionCancerManitoba

Table of Contents	
Introduction to the Data	2
Manitoba's Cancer Profile	3
Facts & Figures)
Most Common Cancers, 2020	3
Cancer Incidence by Site	4
Manitoba Cancer Rates by Regional	
Health Authority (Incidence)	5
Cancer Incidence—Cases & Rates by Site	6
Tumour Staging by Site	8
Deaths by Underlying Cause in	
Manitoba (Mortality)	10
Appendix 1	
International Classification	
Of Disease for Oncology, 3rd Edition	11

Vision

A world free of cancer.

Mission

To reduce and, where possible, eliminate the burden of cancer on the people of Manitoba through exemplary programs of prevention, diagnosis, treatment, rehabilitation, continuing care, research and education.

Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

NOTE: All statistics in the body of this report only include Manitoba residents.

Manitoba Cancer Registry data is used for:

- · health care planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- patient care
- quality assurance
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of Cancer Registries

Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Manitoba Provincial Client Registry
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2020 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See Appendix 1 for the primary site groupings used for incidence.

Mortality data

Mortality information refers to Manitobans who died of cancer in the 2020 calendar year, however, those patients may not have been diagnosed in 2020. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2020, there were 2,595 deaths due to invasive cancer (age standardized rate – 187.1 per 100,000). The totals in the summary on page 10 include all cancer deaths occurring in Manitoba.

Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2011 Manitoba population.

Staging data

The Manitoba Cancer Registry has collected cancer stage for all cases of cancer (excluding non-melanoma skin cancer) diagnosed since January 1, 2004. From 2004 to 2017, collection followed the Collaborative Staging method consistent with the American Joint Committee on Cancer (AJCC) 6th and 7th Tumour, Nodes, and Metastases (TNM) editions. For cancer cases diagnosed January 1, 2018 and forward, cancer stage data is being collected following the AJCC 8th edition of the TNM manual.

In this report, stage data is shown for all disease site groups with a cancer incidence of 45 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 8. Due to changes in the staging system, this year we have presented data as early and intermediate stage, and late stage.

Population data

Data are based on Manitoba estimates provided by Manitoba Health.

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:

1-877-787-1272 (toll-free), or CCMBepireg@cancercare.mb.ca

Manitoba's Cancer Profile

Facts & Figures

Manitoba's cancer profile

Cancer is a significant health issue. In 2020, 11,334 Manitobans were diagnosed with cancer:

- 6,884 invasive cancers
- 4,018 in situ (confined to the area of origin)
- 332 unspecified cancers
- 100 benign brain and CNS (central nervous system)

In this same year, **2,595** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.


Most Common Cancer Diagnoses, 2020


Incidence


Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	913	Breast	911	Lung & bronchus	928
Lung & bronchus	463	Lung & bronchus	465	Breast	916
Colorectal	419	Colorectal	328	Prostate	913
Kidney	175	Corpus uteri	262	Colorectal	747
Non-Hodgkin Lymphoma	160	Non-Hodgkin Lymphoma	152	Non-Hodgkin Lymphoma	312
Melanoma of the skin	155	Pancreas	118	Melanoma of the skin	271
Bladder	113	Melanoma of the skin	116	Corpus uteri	262
Pancreas	94	Thyroid	101	Kidney	262
Multiple myeloma	73	Ovary	95	Pancreas	212
Stomach	70	Kidney	87	Bladder	142

Cancer Incidence by Site


Invasive cancers only







Manitoba Cancer Rates by Regional Health Authority




2020 All Invasive Cancers Female *Incidence*

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded

2020 All Invasive Cancers Male Incidence

Age-standardized rate per 100,000 Standard population: Manitoba 2011 Out-of-province residents excluded



Cancer Incidence - Cases and Rates in Manitoba by Site, 2020

Buccal cavity & pharymx Gun Oro	Cancer Site ongue ajor salivary gland oor of mouth	M 0	00-29 F 0	Т	М	30-39 F	Т	М	40-49		- 1	50-59			60-69			70-79			80 +			tal Co			ASIR*	
Buccal cavity & pharynx Buccal Cavity & Oro	ongue ajor salivary gland	0			М	F	Т	м	_												_							
Buccal cavity & pharynx Buccal Cavity & Oro	ongue ajor salivary gland		0	_		-		141	F	Т	М	F	Т	M	F	Т	M	F	T	M	F	Т	M	F	T	M	F	Т
Buccal cavity & pharymx Gun Oro	ajor salivary gland	0		0	1	0	1	2	0	2	5	0	5	7	3	10	9	9	18	10	5	15	34	17	51	5.12	1.95	3.39
Buccal cavity & pharym			0	0	5	0	5	2	1	3	13	6	19	12	4	16	9	0	9	2	1	3	43	12	55	6.01	1.72	3.8
Oro	por of mouth	0	0	0	0	0	0	0	2	2	0	0	0	1	0	1	1	1	2	2	1	3	4	4	8	0.63	0.56	0.56
Oro		0	0	0	0	0	0	1	0	1	1	1	2	1	2	3	0	0	0	1	0	1	4	3	7	0.63	0.4	0.5
Oro	ım & other mouth	0	0	0	0	0	0	0	0	0	2	1	3	7	0	7	2	4	6	4	5	9	15	10	25	2.19	1.21	1.68
Oro	sopharynx	0	0	0	0	0	0	3	3	6	1	0	1	2	0	2	0	0	0	0	0	0	6	3	9	0.89	0.49	0.69
Нур	opharynx	0	0	0	0	0	0	3	1	4	1	1	2	2	1	3	1	0	1	0	0	0	7	3	10	1.01	0.44	0.72
	popharynx	0	0	0	0	0	0	0	1	1	2	0	2	1	1	2	1	0	1	0	1	1	4	3	7	0.56	0.41	0.49
Othe	her buccal cavity & pharynx	0	0	0	1	0	1	1	0	1	5	1	6	8	1	9	4	1	5	0	1	1	19	4	23	2.56	0.51	1.53
Eso	ophagus	0	0	0	0	0	0	1	0	1	5	2	7	18	4	22	19	7	26	16	5	21	59	18	77	8.55	2.17	5.04
Stor	omach	0	0	0	1	1	2	4	5	9	8	8	16	23	13	36	20	8	28	14	11	25	70	46	116	10	6	7.8
Sma	nall intestine	0	0	0	1	1	2	1	3	4	4	2	6	6	8	14	10	5	15	3	0	3	25	19	44	3.46	2.44	2.87
Cold	olorectal	3	3	6	11	8	19	20	17	37	76	40	116	123	78	201	113	92	205	73	90	163	419	328	747	60.09	41.05	50.12
e	Colon excluding rectum	2	3	5	4	5	9	8	10	18	35	27	62	69	51	120	79	66	145	45	74	119	242	236	478	34.41	29.42	31.88
Digestive	Rectum & rectosigmoid	1	0	1	7	3	10	12	7	19	41	13	54	54	27	81	34	26	60	28	16	44	177	92	269	25.68	11.63	18.24
Anu	us	0	0	0	0	0	0	0	2	2	1	3	4	5	7	12	2	3	5	0	3	3	8	18	26	1.02	2.34	1.72
Live	/er	1	1	2	0	0	0	7	1	8	10	4	14	23	7	30	19	8	27	8	2	10	68	23	91	9.55	2.91	6.04
Gall	ıllbladder	0	0	0	0	0	0	0	0	0	0	2	2	1	5	6	3	3	6	2	6	8	6	16	22	0.87	1.98	1.47
Pan	ncreas	1	0	1	2	0	2	1	5	6	13	14	27	28	31	59	31	35	66	18	33	51	94	118	212	13.31	14.62	14.03
Othe	her digestive system	0	0	0	2	1	3	2	1	3	4	7	11	18	9	27	20	8	28	8	6	14	54	32	86	7.42	4.1	5.62
	rynx	0	0	0	0	0	0	0	0	0	5	2	7	7	1	8	5	2	7	4	0	4	21	5	26	3.03	0.66	1.74
Respiratory	ng & bronchus	0	0	0	0	0	0	8	5	13	43	40	83	155	127	282	169	188	357	88	105	193	463	465	928	64.68	55.74	59.75
	her respiratory system	1	0	1	0	1	1	1	1	2	0	0	0	0	1	1	2	3	5	0	1	1	4	7	11	0.55	0.86	0.73
Bon	ones & joints	6	1	7	0	0	0	0	0	0	3	1	4	2	1	3	1	0	1	1	0	1	13	3	16	1.92	0.43	1.16
soft Soft	ft tissue (Including heart)	3	2	5	2	0	2	3	1	4	5	4	9	2	4	6	3	6	9	4	1	5	22	18	40	3.36	2.36	2.8
Mesothelial & soft tissue (inc. heart) Read (inc. heart)	posi sarcoma	0	0	0	1	1	2	0	0	0	0	0	0	2	0	2	0	0	0	0	0	0	3	1	4	0.38	0.13	0.26
Mesot tissue	esothelioma	0	1	1	0	1	1	0	0	0	1	1	2	3	2	5	14	0	14	7	1	8	25	6	31	3.57	0.81	2.01
Mela	elanoma of the skin	3	5	8	5	11	16	11	17	28	23	20	43	41	25	66	46	24	70	26	14	40	155	116	271	22.17	15.5	18.38
Brea	east	0	3	3	0	43	43	0	121	121	0	187	187	2	232	234	3	210	213	0	115	115	5	911	916	0.61	120.36	62.8
Cer	rvix uteri	0	3	3	0	13	13	0	19	19	0	8	8	0	9	9	0	3	3	0	2	2	0	57	57	0	8.19	0
Cor	orpus uteri	0	1	1	0	5	5	0	21	21	0	70	70	0	91	91	0	48	48	0	26	26	0	262	262	0	34.73	0
Female genital	erus, NOS	0	0	0	0	0	0	0	0	0	0	3	3	0	2	2	0	4	4	0	0	0	0	9	9	0	1.15	0
Ova	vary	0	2	2	0	3	3	0	9	9	0	19	19	0	28	28	0	21	21	0	13	13	0	95	95	0	12.44	0
Othe	her female genital system	0	1	1	0	2	2	0	1	1	0	7	7	0	16	16	0	9	9	0	12	12	0	48	48	0	6.07	0

		Age group																			ININUA	ACID*						
	Cancer Site		00-29			30-39			40-49)		50-5			60-69			70-79			80+		Тс	otal Co	unt		ASIR*	
		М	F	Т	М	F	Т	М	F	Т	М	F	Т	M	F	Т	М	F	Т	M	F	Т	M	F	Т	М	F	Т
_	Prostate	0	0	0	0	0	0	10	0	10	108	0	108	353	0	353	307	0	307	135	0	135	913	0	913	125.61	0	0
Male genital	Testis	14	0	14	10	0	10	6	0	6	4	0	4	0	0	0	1	0	1	0	0	0	35	0	35	5.13	0	0
Male	Penis	0	0	0	0	0	0	0	0	0	1	0	1	4	0	4	2	0	2	4	0	4	11	0	11	1.66	0	0
	Other male genital system	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.15	0	0
	Bladder	1	0	1	2	1	3	0	3	3	4	3	7	29	2	31	35	8	43	42	12	54	113	29	142	16.91	3.68	9.46
Urinary	Kidney	2	0	2	10	4	14	19	7	26	32	13	45	53	24	77	37	27	64	22	12	34	175	87	262	25.03	11.02	17.67
.i.	Ureter	0	0	0	0	0	0	0	0	0	1	0	1	2	1	3	0	2	2	3	1	4	6	4	10	0.98	0.46	0.68
	Other urinary system	1	0	1	0	0	0	0	0	0	1	0	1	3	1	4	1	1	2	5	1	6	11	3	14	1.75	0.35	0.96
	Еуе	1	4	5	0	0	0	0	0	0	2	1	3	2	1	3	1	1	2	0	1	1	6	8	14	0.83	1.13	0.99
Brain & other CNS	Brain	8	3	11	3	3	6	2	4	6	6	2	8	19	6	25	10	12	22	8	5	13	56	35	91	7.95	4.46	6.11
Bra	Other nervous system	1	1	2	1	1	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	2	3	5	0.28	0.45	0.36
Endocrine	Thyroid	3	14	17	4	11	15	7	22	29	10	22	32	4	15	19	7	12	19	1	5	6	36	101	137	5.23	14.41	9.86
Endo	Other endocrine	1	1	2	1	2	3	1	1	2	4	0	4	1	1	2	1	0	1	0	2	2	9	7	16	1.32	0.95	1.16
aa	Hodgkin lymphoma	6	6	12	1	6	7	2	1	3	1	1	2	0	1	1	3	1	4	2	0	2	15	16	31	2.25	2.27	2.21
Lymphoma	Non-Hodgkin lymphoma	7	4	11	7	6	13	9	9	18	27	19	46	32	41	73	56	42	98	22	31	53	160	152	312	22.67	19.19	20.84
	Multiple myeloma	0	0	0	0	0	0	3	5	8	12	2	14	17	7	24	29	15	44	12	8	20	73	37	110	10.31	4.58	7.24
	Acute lymphocytic leukemia	15	6	21	0	0	0	1	2	3	1	2	3	0	0	0	0	1	1	0	1	1	17	12	29	2.54	1.8	2.2
	Chronic lymphocytic leukemia	0	0	0	0	0	0	1	1	2	8	6	14	20	8	28	20	14	34	15	5	20	64	34	98	9.2	4.21	6.43
Leukemias	Acute myeloid leukemia	3	4	7	1	2	3	1	1	2	6	6	12	10	6	16	8	11	19	6	3	9	35	33	68	5.05	4.28	4.58
Leuk	Acute monocytic leukemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	1	2	0.12	0.12	0.13
	Chronic myeloid leukemia	2	0	2	0	0	0	2	0	2	3	1	4	2	1	3	1	3	4	1	0	1	11	5	16	1.65	0.6	1.12
	Other leukemias	0	0	0	0	0	0	0	1	1	0	0	0	3	4	7	1	2	3	1	0	1	5	7	12	0.68	0.86	0.76
	Other ill defined & unknown	1	3	4	2	1	3	2	3	5	22	8	30	21	17	38	30	39	69	36	40	76	114	111	225	17.34	13.54	15.24
	TOTAL - ALL INVASIVE	85	69	154	74	128	202	137	297	434	484	541	1025	1075	849	1924	1058	893	1951	606	588	1194	3519	3365	6884	498.79	433.07	460.05
	Non-Melanoma skin & in situ skin	5	4	9	18	43	61	55	92	147	185	177	362	449	350	799	611	373	984	419	381	800	1742	1420	3162	251.24	178.73	210.3
	Breast in situ	0	0	0	0	4	4	0	8	8	1	29	30	0	22	22	0	18	18	0	2	2	1	83	84	0.16	11.29	5.82
	Cervix in situ	0	136	136	0	158	158	0	59	59	0	37	37	0	21	21	0	4	4	0	1	1	0	416	416	0	60.42	0
In situ	Prostate in situ	0	0	0	0	0	0	0	0	0	6	0	6	13	0	13	12	0	12	2	0	2	33	0	33	4.4	0	0
	Bladder in situ	0	0	0	2	0	2	3	2	5	18	5	23	42	12	54	60	19	79	31	12	43	156	50	206	22.02	6.1	13.4
	Colorectal in situ	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	1	0	0	0	1	1	2	0.16	0.11	0.14
	Other in situ (Excl. Breast, Skin, Cervix, Prostate, Bladder, Colorectal)	0	1	1	0	7	7	2	9	11	5	26	31	14	18	32	10	17	27	2	6	8	33	84	117	4.45	11.43	7.99
	TOTAL - INVASIVE + IN SITU	90	210	300	94	340	434	197	467	664	700	815	1515	1593	1272	2865	1751	1325	3076	1060	990	2050	5485	5419	10902	781.23	701.15	729.86
	Brain uncertain & unspecified	3	0	3	2	4	6	1	3	4	0	2	2	3	4	7	2	4	6	1	0	1	12	17	29	1.68	2.25	1.95
	Neoplasms (Uncertain & unspecified, excluding brain)	8	14	22	7	10	17	6	14	20	22	23	45	32	35	67	50	32	82	27	23	50	152	151	303	21.77	19.92	20.51
	Brain & nervous system benign	3	0	3	2	2	4	7	7	14	8	12	20	5	19	24	2	17	19	7	9	16	34	66	100	5.3	8.55	6.96
	ALL CANCERS	104	224	328	105	356	461	211	491	702	730	852	1582	1633	1330	2963	1805	1378	3183	1095	1022	2117	5683	5653	11334	809.98	731.86	759.28
	*Age standardized incidence rate per 100.000								1																			

*Age standardized incidence rate per 100,000 Standard Population: Manitoba 2011

Tumour Staging by Site

Staging on sites with more than 45 cases

LIP

Stage	Frequency	Percent	
Early/Intermediate	47	92.16	
Late	4	7.84	
Total	51	100	



COLON EXCLUDING RECTUM

Stage	Frequency	Percent	
Early/Intermediate	380	79.50	
Late	98	20.50	
Total	478	100	



TONGUE

Stage	Frequency	Percent	
Early/Intermediate	44	80.00	
Late	11	20.00	
Total	55	100	



RECTUM & RECTOSIGMOID

Stage	Frequency	Percent	
Early/Intermediate	216	80.30	
Late	53	19.70	
Total	269	100	



ESOPHAGUS

Stage	Frequency	Percent	
Early/Intermediate	49	63.64	
Late	28	36.36	
Total	77	100	



LIVER

Stage	Frequency	Percent	
Early/Intermediate	80	87.91	
Late	11	12.09	
Total	91	100	



STOMACH

Stage	Frequency	Percent	
Early/Intermediate	62	53.45	
Late	54	46.55	
Total	116	100	



PANCREAS

Stage	Frequency	Percent	
Early/Intermediate	112	52.83	
Late	100	47.17	
Total	212	100	



COLORECTAL

COLONLCTAL			
Stage	Frequency	Percent	
Early/Intermediate	596	79.79	
Late	151	20.21	
Total	747	100	Г



OTHER DIGESTIVE SYSTEM

Stage	Frequency	Percent	
Early/Intermediate	72	83.72	
Late	14	16.28	
Total	86	100	



BREAST

Stage	Frequency	Percent	
Early/Intermediate	850	92.79	
Late	66	7.21	
Total	916	100	



LUNG & BRONCHUS

Stage	Frequency	Percent	
Early/Intermediate	469	50.54	
Late	459	49.46	
Total	928	100	



^{*}Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.

^{**}In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

CERVIX UTERI

Stage	Frequency	Percent	
Early/Intermediate	55	96.49	
Late	2	3.51	
Total	57	100	



			\sim		_			
M	_	 M		M/I //		ΤН	-	

Stage	Frequency	Percent	
Early/Intermediate	263	97.05	
Late	8	2.95	
Total	271	100	



CORPUS UTERI

Stage	Frequency	Percent	
Early/Intermediate	247	94.27	
Late	15	5.73	
Total	262	100	



PROSTATE

Stage	Frequency	Percent	
Early/Intermediate	766	83.90	
Late	147	16.10	
Total	913	100	



OVARY

Stage	Frequency	Percent	
Early/Intermediate	67	70.53	
Late	28	29.47	
Total	95	100	



BLADDER

Stage	Frequency	Percent	
Early/Intermediate	117	82.39	
Late	25	17.61	
Total	142	100	



OTHER FEMALE GENITAL SYSTEM

Stage	Frequency	Percent	
Early/Intermediate	41	85.42	
Late	7	14.58	
Total	48	100	



KIDNEY

Stage	Frequency	Percent	
Early/Intermediate	218	83.21	
Late	44	16.79	
Total	262	100	



NON-HODGKIN LYMPHOMA

Stage	Frequency	Percent	
Early/Intermediate	191	61.22	
Late	121	38.78	
Total	312	100	



THYROID

Stage	Frequency	Percent	
Early/Intermediate	131	95.62	
Late	6	4.38	
Total	137	100	



CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA

SMALL LIMI HOCI HC LIMI HOMA				
Stage	Frequency	Percent		
Early/Intermediate	86	87.76		
Late	12	12.24		
Total	98	100		



^{**}Using Lugano and/or RAI stage

^{*}Early/Intermediate includes non-metastatic and unknown stage cancer diagnoses, while Late stage includes metastatic cancer diagnoses.

^{**}In keeping with international coding conventions, all invasive brain tumors, multiple myeloma and non-CLL leukemia are considered unstageable using the AJCC TNM 8th edition staging system utilized by all population-based North American Cancer Registries.

Deaths by Underlying Cause in Manitoba¹

(Rate per 100,000)

	2020		2019			2018			
CAUSES OF DEATH	Number	Rate per MB Health Population	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*	Number	Rate per MB Health Population*	Rate per Statistics Canada Population*
Accidents (V01-X59, Y85-Y86)	459	33.1	33.3	497	36.2	36.0	379	27.9	28.0
Cancer (C00 - C97)	2,595	187.1	188.1	2,864	208.6	207.7	2,696	198.2	199.4
Cerebrovascular Disease (I60 - I69)	477	34.4	34.6	595	43.3	43.1	526	38.7	38.9
Diabetes (E10 - E14)	301	21.7	21.8	331	24.1	24.0	315	23.2	23.3
Diseases of the heart (100 - 109, 111, 113, 120 - 125, 126 - 151)	1,883	135.8	136.5	2076	151.2	150.5	1,951	143.4	144.3
Pneumonia (J12 - J18)	140	10.1	10.2	209	15.2	15.2	187	13.7	13.8
Intentional Self-Harm (X60 - X84, Y890)	164	11.8	11.9	192	14.0	13.9	219	16.1	16.2

Reference

¹Vital Statistics Agency, 2020/21 Annual Report. Government of Manitoba; 2021. [cited March 06, 2023].

http://vitalstats.gov.mb.ca/pdf/2021_vs_annual_report_en.pdf

3rd Edition

RIMARY SITE	SITE/ CELL TYPE
Succal cavity and pharynx	C00:C14
Lip	C000:C009
Tongue	C019:C029
Major salivary gland	C079:C089
Floor of mouth	C040:C049
Gum & other mouth	C030:C039, C050:C059, C060:C069
Nasopharynx	C110:C119
Oropharynx	C100:C109
Hypopharynx	C129, C130:C139
Other buccal cavity & pharynx	C090:C099, C140, C142:C148
ligestive system	C15:C26
Esophagus	C150:C159
Stomach	C160:C169
Small intestine	C170:C179
Colon excluding rectum	C180:C189, C260
Rectum & Rectosigmoid	C199, C209
Anus	C210:C212, C218
Liver	C220
Gallbladder	C239
Pancreas	C250:C259
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269
	C488
espiratory system	C30:C39
Larynx	C320:C329
Lung & bronchus	C340:C349
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383 C388, C390:C399
Bones & joints	C400:C419
Soft tissue (including heart)	C380, C470:C479, C490:C499
Mesothelioma	9050:9055
Kaposi sarcoma	9140
Skin	C44
Melanomas of the skin	C440:C449 (8720:8790)
Other skin	C440:C449
Breast	C500:C509
Female genital system	C51:C58
Cervix uteri	C530:C539
Corpus uteri	C540:C549
Uterus, NOS	C559
Ovary	C569
Other female genital system	C529, C510:C519, C570:C589

PRIMARY SITE	SITE/ CELL TYPE
Male genital system	C60:C63
Prostate	C619
Testis	C620:C629
Penis	C600:C609
Other male genital system	C630:C639
Urinary system	C64:C68
Bladder (incl. <i>in situ</i>)	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
Еуе	C690:C699
Brain & other nervous system	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 (953), C700:C709. C720:C729
Endocrine	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
Lymphomas	
Hodgkin lymphoma	9650-9667
Non-Hodgkin lymphoma	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738 9811-9818 (except C420, C421, C424) 9823 (except C420, C421, C424)
Myeloma	9827 (except C420, C421, C424) 9837 (except C420, C421, C424) 9731-9732, 9734
Leukemias	(42
Acute lymphocytic Chronic lymphocytic	9826, 9835-9836 9811-9818 (only C421) 9837 (only C421) 9823 (only C421, if SLL C77)
Acute myeloid	9840, 9861, 9865-9867, 9869, 9871-9874, 9895-
Acute monocytic	9897, 9898, 9910-9911, 9920, 9891
Chronic myeloid	9863, 9875-9876, 9945-9946
Other	9733, 9742, 9800, 9801, 9805-9809, 9820, 9831-
Ollici	9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964 9827 (only C421)
Other, ill-defined, & unknown	9740-9741, 9750-9769, 9950, 9960-9962, 9965- 9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992
	C420-C424 (except 9050-9055, 9140, 9590-9992) C760-C768 (except 9050-9055, 9140, 9590-9992) C770-C779 (except 9050-9055, 9140, 9590-9992) C809 (except 9050-9055, 9140, 9590-9992)

CONTACT DETAILS

Epidemiology and Cancer Registry CancerCare Manitoba 675 McDermot Ave. Winnipeg, MB R3E 0V9 Main line: (204) 787-2174

Email: CCMBepireg@cancercare.mb.ca

TO CITE THIS REPORT

 $\label{lem:condition} \textbf{Department of Epidemiology and Cancer Registry, Cancer Care\ Manitoba.}$

"Cancer in Manitoba, 2020 Annual Statistical Report."

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at www.cancercare.mb.ca

